GeoVax Q3 net loss $6.3M ($0.31/sh); BARDA contract terminated; Mpox vaccine accelerated

GeoVax Labs, Inc.

Net loss of $6.3M vs $5.8M in Q3 2024; per-share loss improved to $0.31 from $0.91 due to share count change.
Revenue fell to $0 as BARDA terminated Project NextGen contract for convenience in April 2025, compared to $2.8M in Q3 2024.
Cash $5.0M at Sep 30, 2025, down from $5.5M at Dec 31, 2024; burn rate continues.
GEO-MVA accelerated amid global Mpox emergency; EMA supports streamlined regulatory pathway.
GEO-CM04S1 met primary endpoint in CLL trial; Gedeptin expanding into new solid tumor indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.